(WQOW) - On Saturday, the FDA authorized emergency use for the Johnson & Johnson vaccine, so what makes this third option different from the Pfizer and Moderna vaccines?
As of now, the Janssen COVID-19 vaccine, better known as the Johnson & Johnson vaccine, is just a single dose versus its predecessors which require two.
Both Pfizer and Modern have an efficacy rate of about 95%, but J&J is at just 67% efficacy in preventing moderate to severe illness.
Dr. Matt Anderson, senior medical director of primary care at UW Health, said this new vaccine will also help prevent the risk of hospitalization and death, and that just a single dose is needed because the process to create it was different.
"They're different mechanisms of action," Anderson said. "The Moderna, Pfizer being mRNA-based vaccines as compared to adenovirus-based vaccine for Johnson & Johnson. So, they're different. It's apples and oranges a little bit. Same topic. Building an immune response against the same virus, but doing it in different ways."
Anderson said Johnson & Johnson is looking at doing a two-dose trial in the future.
This comes as educators and child care workers become eligible to receive the vaccine Monday, Mar. 1.